CONSTANCEALBARRACINCONSTANCE ALBARRACIN8954ALBARRACIN, CONSTANCEProfessorprns:coAuthorOfcoauthor ofFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:similarTosimilar toprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierAddressvivo:address1address line 1vivo:addressCitycityvivo:addressPostalCodepostal codevivo:addressStatestate or provincevivo:authorInAuthorshipselected publicationsvivo:authorRankauthor rank in publicationAuthorshipDepartmentDivisionvivo:hasResearchArearesearch areasvivo:hrJobTitleHR job titleInformation Resourcevivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcevivo:mailingAddressmailing addressvivo:personInPositionpositionsPositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPerson1515 Holcombe BlvdHouston77030-4009TXAuthorship 1755752Authorship 18266213Authorship 1827274Authorship 1853701Authorship 1854054Authorship 1864581Authorship 1870083Authorship 1883447Authorship 1884232Authorship 1884963Authorship 1892638Authorship 18948112Authorship 1902723Authorship 1913447Authorship 194284316445630Chang KH, Albarracin C, Luthra R, Wang L, Zheng W, Malpica A, Deavers MT, Silva EG, Liu JInternational journal of gynecological cancer : official journal of the International Gynecological Cancer SocietyDiscordant genetic changes in ovarian and endometrial endometrioid carcinomas: a potential pitfall in molecular diagnosis. Int J Gynecol Cancer. 2006 Jan-Feb; 16(1):178-82.Int J Gynecol Cancer2006-01-01T00:00:002006Discordant genetic changes in ovarian and endometrial endometrioid carcinomas: a potential pitfall in molecular diagnosis.18663355Luthra R, Singh RR, Luthra MG, Li YX, Hannah C, Romans AM, Barkoh BA, Chen SS, Ensor J, Maru DM, Broaddus RR, Rashid A, Albarracin CTOncogeneMicroRNA-196a targets annexin A1: a microRNA-mediated mechanism of annexin A1 downregulation in cancers. Oncogene. 2008 Nov 06; 27(52):6667-78.Oncogene2008-07-28T00:00:002008MicroRNA-196a targets annexin A1: a microRNA-mediated mechanism of annexin A1 downregulation in cancers.20121597Albarracin C, Edgerton ME, Gilcrease MZ, Huo L, Krishnamurthy S, Middleton LP, Resetkova E, Sahin AA, Sneige N, Fraser WS, Wu YArchives of pathology & laboratory medicineIs it too soon to start reporting HER2 genetic heterogeneity? Arch Pathol Lab Med. 2010 Feb; 134(2):162-3; author reply 163.Arch Pathol Lab Med2010-02-01T00:00:002010Is it too soon to start reporting HER2 genetic heterogeneity?20564633Dawood S, Gonzalez-Angulo AM, Albarracin C, Yu TK, Hortobagyi GN, Buchholz TA, Woodward WACancerPrognostic factors of survival in the trastuzumab era among women with breast cancer and brain metastases who receive whole brain radiotherapy: a single-institution review. Cancer. 2010 Jul 01; 116(13):3084-92.Cancer2010-07-01T00:00:002010Prognostic factors of survival in the trastuzumab era among women with breast cancer and brain metastases who receive whole brain radiotherapy: a single-institution review.20814820Wu X, Chen F, Sahin A, Albarracin C, Pei Z, Zou X, Singh B, Xu R, Daniels G, Li Y, Wei J, Blake M, Schneider RJ, Cowin P, Lee PBreast cancer research and treatmentDistinct function of androgen receptor coactivator ARA70a and ARA70? in mammary gland development, and in breast cancer. Breast Cancer Res Treat. 2011 Jul; 128(2):391-400.Breast Cancer Res Treat2010-09-03T00:00:002010Distinct function of androgen receptor coactivator ARA70a and ARA70? in mammary gland development, and in breast cancer.21084420Albarracin CT, Nguyen CV, Whitman GJ, Yang W, Weiang W, Sneige NRadiologyIdentifying patients with atypical ductal hyperplasia diagnosed at core-needle biopsy who are at low risk of malignancy. Radiology. 2010 Dec; 257(3):893-4; author reply 984.Radiology2010-12-01T00:00:002010Identifying patients with atypical ductal hyperplasia diagnosed at core-needle biopsy who are at low risk of malignancy.21372145Shehu A, Albarracin C, Devi YS, Luther K, Halperin J, Le J, Mao J, Duan RW, Frasor J, Gibori GMolecular endocrinology (Baltimore, Md.)The stimulation of HSD17B7 expression by estradiol provides a powerful feed-forward mechanism for estradiol biosynthesis in breast cancer cells. Mol Endocrinol. 2011 May; 25(5):754-66.Mol Endocrinol2011-03-03T00:00:002011The stimulation of HSD17B7 expression by estradiol provides a powerful feed-forward mechanism for estradiol biosynthesis in breast cancer cells.22009639Bayraktar S, Elsayegh N, Gutierrez Barrera AM, Lin H, Kuerer H, Tasbas T, Muse KI, Ready K, Litton J, Meric-Bernstam F, Hortobagyi GN, Albarracin CT, Arun BCancerPredictive factors for BRCA1/BRCA2 mutations in women with ductal carcinoma in situ. Cancer. 2012 Mar 15; 118(6):1515-22.Cancer2011-08-25T00:00:002011Predictive factors for BRCA1/BRCA2 mutations in women with ductal carcinoma in situ.24589259Wang J, Wei B, Albarracin CT, Hu J, Abraham SC, Wu YBMC cancerInvasive neuroendocrine carcinoma of the breast: a population-based study from the surveillance, epidemiology and end results (SEER) database. BMC Cancer. 2014 Mar 04; 14:147.BMC Cancer2014-03-04T00:00:002014Invasive neuroendocrine carcinoma of the breast: a population-based study from the surveillance, epidemiology and end results (SEER) database.Breast Medical OncologyInvestigational Cancer TherapeuticsMD AndersonHENRY MARKKUERERHENRY MARK KUERER8727KUERER, HENRY MARKProfessorLEIHUOLEI HUO9168HUO, LEIAssociate ProfessorKELLY KHUNTKELLY K HUNT8555HUNT, KELLY KProfessorAYSEGUL ASAHINAYSEGUL A SAHIN8608SAHIN, AYSEGUL AProfessorISABELLEBEDROSIANISABELLE BEDROSIAN8959BEDROSIAN, ISABELLEProfessorELIZABETH ANNMITTENDORFELIZABETH ANN MITTENDORF9277MITTENDORF, ELIZABETH ANNAssociate ProfessorFUNDAMERIC-BERNSTAMFUNDA MERIC-BERNSTAM8778MERIC-BERNSTAM, FUNDAProfessorBANU KARUNBANU K ARUN8898ARUN, BANU KProfessor1.893420.00543961395research areas2.275660.0161956118coauthor of70.911714.664560similar to11114selected publicationsERIKARESETKOVAERIKA RESETKOVA9013RESETKOVA, ERIKAAssociate ProfessorAuthorship 2181471Authorship 2211383Authorship 2219632Authorship 22323110Authorship 2232372Authorship 22403411Authorship 2243245Authorship 2247886Authorship 2255702Authorship 2261062Authorship 22626511Authorship 2273333Authorship 2274467Authorship 2288382Authorship 2289232Authorship 2298876Authorship 2304076Authorship 23048111Authorship 2311538Authorship 2323807Authorship 234845510872659Albarracin CT, Jafri J, Montag AG, Hart J, Kuan SFHuman pathologyDifferential expression of MUC2 and MUC5AC mucin genes in primary ovarian and metastatic colonic carcinoma. Hum Pathol. 2000 Jun; 31(6):672-7.Hum Pathol2000-06-01T00:00:002000Differential expression of MUC2 and MUC5AC mucin genes in primary ovarian and metastatic colonic carcinoma.14631366Liu J, Albarracin CT, Chang KH, Thompson-Lanza JA, Zheng W, Gershenson DM, Broaddus R, Luthra RModern pathology : an official journal of the United States and Canadian Academy of Pathology, IncMicrosatellite instability and expression of hMLH1 and hMSH2 proteins in ovarian endometrioid cancer. Mod Pathol. 2004 Jan; 17(1):75-80.Mod Pathol2004-01-01T00:00:002004Microsatellite instability and expression of hMLH1 and hMSH2 proteins in ovarian endometrioid cancer.15528963Wang B, Rouzier R, Albarracin CT, Sahin A, Wagner P, Yang Y, Smith TL, Meric-Bernstam F, Marcelo Aldaz C, Marcelo AC, Hortobagyi GN, Pusztai LBreast cancer research and treatmentExpression of sigma 1 receptor in human breast cancer. Breast Cancer Res Treat. 2004 Oct; 87(3):205-14.Breast Cancer Res Treat2004-10-01T00:00:002004Expression of sigma 1 receptor in human breast cancer.16322343Symmans WF, Fiterman DJ, Anderson SK, Ayers M, Rouzier R, Dunmire V, Stec J, Valero V, Sneige N, Albarracin C, Wu Y, Ross JS, Wagner P, Theriault RL, Arun B, Kuerer H, Hess KR, Zhang W, Hortobagyi GN, Pusztai LEndocrine-related cancerA single-gene biomarker identifies breast cancers associated with immature cell type and short duration of prior breastfeeding. Endocr Relat Cancer. 2005 Dec; 12(4):1059-69.Endocr Relat Cancer2005-12-01T00:00:002005A single-gene biomarker identifies breast cancers associated with immature cell type and short duration of prior breastfeeding.16330938Resetkova E, Albarracin C, Sneige NThe American journal of surgical pathologyCollagenous spherulosis of breast: morphologic study of 59 cases and review of the literature. Am J Surg Pathol. 2006 Jan; 30(1):20-7.Am J Surg Pathol2006-01-01T00:00:002006Collagenous spherulosis of breast: morphologic study of 59 cases and review of the literature.16899607Wang KL, Wu TT, Resetkova E, Wang H, Correa AM, Hofstetter WL, Swisher SG, Ajani JA, Rashid A, Hamilton SR, Albarracin CTClinical cancer research : an official journal of the American Association for Cancer ResearchExpression of annexin A1 in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome. Clin Cancer Res. 2006 Aug 01; 12(15):4598-604.Clin Cancer Res2006-08-01T00:00:002006Expression of annexin A1 in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome.17870021May SA, Deavers MT, Resetkova E, Johnson D, Albarracin CTAnnals of diagnostic pathologyGiant cell tumor of soft tissue arising in breast. Ann Diagn Pathol. 2007 Oct; 11(5):345-9.Ann Diagn Pathol2007-07-24T00:00:002007Giant cell tumor of soft tissue arising in breast.18043978Dawood S, Broglio K, Gonzalez-Angulo AM, Kau SW, Yang W, Albarracin C, Meric F, Hortobagyi G, Theriault RAnnals of surgical oncologyDevelopment of new cancers in patients with DCIS: the M.D. Anderson experience. Ann Surg Oncol. 2008 Jan; 15(1):244-9.Ann Surg Oncol2007-11-28T00:00:002007Development of new cancers in patients with DCIS: the M.D. Anderson experience.18300793Khalifeh IM, Albarracin C, Diaz LK, Symmans FW, Edgerton ME, Hwang RF, Sneige NThe American journal of surgical pathologyClinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma. Am J Surg Pathol. 2008 Apr; 32(4):544-52.Am J Surg Pathol2008-04-01T00:00:002008Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma.18626769Resetkova E, Edelweiss M, Albarracin CT, Yang WTBreast cancer research and treatmentManagement of radial sclerosing lesions of the breast diagnosed using percutaneous vacuum-assisted core needle biopsy: recommendations for excision based on seven years' of experience at a single institution. Breast Cancer Res Treat. 2011 Jun; 127(2):335-43.Breast Cancer Res Treat2008-07-15T00:00:002008Management of radial sclerosing lesions of the breast diagnosed using percutaneous vacuum-assisted core needle biopsy: recommendations for excision based on seven years' of experience at a single institution.19064970Kuerer HM, Albarracin CT, Yang WT, Cardiff RD, Brewster AM, Symmans WF, Hylton NM, Middleton LP, Krishnamurthy S, Perkins GH, Babiera G, Edgerton ME, Czerniecki BJ, Arun BK, Hortobagyi GNJournal of clinical oncology : official journal of the American Society of Clinical OncologyDuctal carcinoma in situ: state of the science and roadmap to advance the field. J Clin Oncol. 2009 Jan 10; 27(2):279-88.J Clin Oncol2008-12-08T00:00:002008Ductal carcinoma in situ: state of the science and roadmap to advance the field.19150943Dawood S, Broglio K, Esteva FJ, Yang W, Kau SW, Islam R, Albarracin C, Yu TK, Green M, Hortobagyi GN, Gonzalez-Angulo AMAnnals of oncology : official journal of the European Society for Medical OncologySurvival among women with triple receptor-negative breast cancer and brain metastases. Ann Oncol. 2009 Apr; 20(4):621-7.Ann Oncol2009-01-15T00:00:002009Survival among women with triple receptor-negative breast cancer and brain metastases.19174581Arun B, Vogel KJ, Lopez A, Hernandez M, Atchley D, Broglio KR, Amos CI, Meric-Bernstam F, Kuerer H, Hortobagyi GN, Albarracin CTCancer prevention research (Philadelphia, Pa.)High prevalence of preinvasive lesions adjacent to BRCA1/2-associated breast cancers. Cancer Prev Res (Phila). 2009 Feb; 2(2):122-7.Cancer Prev Res (Phila)2009-01-27T00:00:002009High prevalence of preinvasive lesions adjacent to BRCA1/2-associated breast cancers.20972636Nguyen CV, Albarracin CT, Whitman GJ, Lopez A, Sneige NAnnals of surgical oncologyAtypical ductal hyperplasia in directional vacuum-assisted biopsy of breast microcalcifications: considerations for surgical excision. Ann Surg Oncol. 2011 Mar; 18(3):752-61.Ann Surg Oncol2010-10-23T00:00:002010Atypical ductal hyperplasia in directional vacuum-assisted biopsy of breast microcalcifications: considerations for surgical excision.21134526Whitman GJ, Albarracin CT, Gonzalez-Angulo AMSeminars in roentgenologyTriple-negative breast cancer: what the radiologist needs to know. Semin Roentgenol. 2011 Jan; 46(1):26-39.Semin Roentgenol2011-01-01T00:00:002011Triple-negative breast cancer: what the radiologist needs to know.21482991Moulder S, Moroney J, Helgason T, Wheler J, Booser D, Albarracin C, Morrow PK, Koenig K, Kurzrock RJournal of clinical oncology : official journal of the American Society of Clinical OncologyResponses to liposomal Doxorubicin, bevacizumab, and temsirolimus in metaplastic carcinoma of the breast: biologic rationale and implications for stem-cell research in breast cancer. J Clin Oncol. 2011 Jul 01; 29(19):e572-5.J Clin Oncol2011-04-11T00:00:002011Responses to liposomal Doxorubicin, bevacizumab, and temsirolimus in metaplastic carcinoma of the breast: biologic rationale and implications for stem-cell research in breast cancer.21668471Tang F, Wei B, Tian Z, Gilcrease MZ, Huo L, Albarracin CT, Resetkova E, Zhang H, Sahin A, Chen J, Bu H, Abraham S, Wu YHistopathologyInvasive mammary carcinoma with neuroendocrine differentiation: histological features and diagnostic challenges. Histopathology. 2011 Jul; 59(1):106-15.Histopathology2011-06-13T00:00:002011Invasive mammary carcinoma with neuroendocrine differentiation: histological features and diagnostic challenges.21830012Bayraktar S, Gutierrez-Barrera AM, Liu D, Tasbas T, Akar U, Litton JK, Lin E, Albarracin CT, Meric-Bernstam F, Gonzalez-Angulo AM, Hortobagyi GN, Arun BKBreast cancer research and treatmentOutcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations. Breast Cancer Res Treat. 2011 Nov; 130(1):145-53.Breast Cancer Res Treat2011-08-10T00:00:002011Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations.21900106Arun B, Bayraktar S, Liu DD, Gutierrez Barrera AM, Atchley D, Pusztai L, Litton JK, Valero V, Meric-Bernstam F, Hortobagyi GN, Albarracin CJournal of clinical oncology : official journal of the American Society of Clinical OncologyResponse to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience. J Clin Oncol. 2011 Oct 01; 29(28):3739-46.J Clin Oncol2011-09-06T00:00:002011Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience.22392043Kuerer HM, Lari SA, Arun BK, Hu CY, Brewster A, Mittendorf EA, Albarracin CT, Babiera GV, Caudle AS, Wagner JL, Litton JK, Bedrosian I, Meric-Bernstam F, Lucci A, Hunt KKBreast cancer research and treatmentBiologic features and prognosis of ductal carcinoma in situ are not adversely impacted by initial large body mass. Breast Cancer Res Treat. 2012 Jun; 133(3):1131-41.Breast Cancer Res Treat2012-03-04T00:00:002012Biologic features and prognosis of ductal carcinoma in situ are not adversely impacted by initial large body mass.25074542Xiang DB, Wei B, Abraham SC, Huo L, Albarracin CT, Zhang H, Babiera G, Caudle AS, Akay CL, Rao P, Zhao YJ, Lu X, Wu YHuman pathologyMolecular cytogenetic characterization of mammary neuroendocrine carcinoma. Hum Pathol. 2014 Sep; 45(9):1951-6.Hum Pathol2014-06-18T00:00:002014Molecular cytogenetic characterization of mammary neuroendocrine carcinoma.Authorship 2381121Authorship 2458051Authorship 2466112Authorship 2478664Authorship 2480112Authorship 2495094Authorship 2498258Authorship 2498747Authorship 2510321Authorship 2524003Authorship 2528397Authorship 2547433Authorship 2566755Authorship 258700128126003Albarracin CT, Palfrey HC, Duan WR, Rao MC, Gibori GThe Journal of biological chemistryProlactin regulation of the calmodulin-dependent protein kinase III elongation factor-2 system in the rat corpus luteum. J Biol Chem. 1994 Mar 11; 269(10):7772-6.J Biol Chem1994-03-11T00:00:001994Prolactin regulation of the calmodulin-dependent protein kinase III elongation factor-2 system in the rat corpus luteum.15138928Cai KQ, Albarracin C, Rosen D, Zhong R, Zheng W, Luthra R, Broaddus R, Liu JHuman pathologyMicrosatellite instability and alteration of the expression of hMLH1 and hMSH2 in ovarian clear cell carcinoma. Hum Pathol. 2004 May; 35(5):552-9.Hum Pathol2004-05-01T00:00:002004Microsatellite instability and alteration of the expression of hMLH1 and hMSH2 in ovarian clear cell carcinoma.15547740Albarracin CT, Silva EG, Malpica A, Luthra R, Liu JOncology reportsThe role of hMSH3 and hMSH6 in ovarian endometrioid carcinoma and relationship with microsatellite instability phenotype. Oncol Rep. 2004 Dec; 12(6):1217-9.Oncol Rep2004-12-01T00:00:002004The role of hMSH3 and hMSH6 in ovarian endometrioid carcinoma and relationship with microsatellite instability phenotype.16594759Anderson P, Albarracin CT, Resetkova EArchives of pathology & laboratory medicineA large, fungating breast mass. Secretory carcinoma with apocrine differentiation. Arch Pathol Lab Med. 2006 Apr; 130(4):e50-2.Arch Pathol Lab Med2006-04-01T00:00:002006A large, fungating breast mass. Secretory carcinoma with apocrine differentiation.16977650Huo L, Sneige N, Hunt KK, Albarracin CT, Lopez A, Resetkova ECancerPredictors of invasion in patients with core-needle biopsy-diagnosed ductal carcinoma in situ and recommendations for a selective approach to sentinel lymph node biopsy in ductal carcinoma in situ. Cancer. 2006 Oct 15; 107(8):1760-8.Cancer2006-10-15T00:00:002006Predictors of invasion in patients with core-needle biopsy-diagnosed ductal carcinoma in situ and recommendations for a selective approach to sentinel lymph node biopsy in ductal carcinoma in situ.17172821He J, Pan Y, Hu J, Albarracin C, Wu Y, Dai JLCancer biology & therapyProfile of Ets gene expression in human breast carcinoma. Cancer Biol Ther. 2007 Jan; 6(1):76-82.Cancer Biol Ther2007-01-01T00:00:002007Profile of Ets gene expression in human breast carcinoma.18084246Ferreira M, Albarracin CT, Resetkova EModern pathology : an official journal of the United States and Canadian Academy of Pathology, IncPseudoangiomatous stromal hyperplasia tumor: a clinical, radiologic and pathologic study of 26 cases. Mod Pathol. 2008 Feb; 21(2):201-7.Mod Pathol2007-12-14T00:00:002007Pseudoangiomatous stromal hyperplasia tumor: a clinical, radiologic and pathologic study of 26 cases.18091390Gokhale S, Rosen D, Sneige N, Diaz LK, Resetkova E, Sahin A, Liu J, Albarracin CTApplied immunohistochemistry & molecular morphology : AIMMAssessment of two automated imaging systems in evaluating estrogen receptor status in breast carcinoma. Appl Immunohistochem Mol Morphol. 2007 Dec; 15(4):451-5.Appl Immunohistochem Mol Morphol2007-12-01T00:00:002007Assessment of two automated imaging systems in evaluating estrogen receptor status in breast carcinoma.18176935Wei Y, Xia W, Zhang Z, Liu J, Wang H, Adsay NV, Albarracin C, Yu D, Abbruzzese JL, Mills GB, Bast RC, Hortobagyi GN, Hung MCMolecular carcinogenesisLoss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers. Mol Carcinog. 2008 Sep; 47(9):701-6.Mol Carcinog2008-09-01T00:00:002008Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers.19047898Downs-Kelly E, Nayeemuddin KM, Albarracin C, Wu Y, Hunt KK, Gilcrease MZThe American journal of surgical pathologyMatrix-producing carcinoma of the breast: an aggressive subtype of metaplastic carcinoma. Am J Surg Pathol. 2009 Apr; 33(4):534-41.Am J Surg Pathol2009-04-01T00:00:002009Matrix-producing carcinoma of the breast: an aggressive subtype of metaplastic carcinoma.19596702Liedtke C, Broglio K, Moulder S, Hsu L, Kau SW, Symmans WF, Albarracin C, Meric-Bernstam F, Woodward W, Theriault RL, Kiesel L, Hortobagyi GN, Pusztai L, Gonzalez-Angulo AMAnnals of oncology : official journal of the European Society for Medical OncologyPrognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann Oncol. 2009 Dec; 20(12):1953-8.Ann Oncol2009-07-12T00:00:002009Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer.21070433Resetkova E, Khazai L, Albarracin CT, Arribas EThe breast journalClinical and radiologic data and core needle biopsy findings should dictate management of cellular fibroepithelial tumors of the breast. Breast J. 2010 Nov-Dec; 16(6):573-80.Breast J2010-11-01T00:00:002010Clinical and radiologic data and core needle biopsy findings should dictate management of cellular fibroepithelial tumors of the breast.22231447Li X, Lu Y, Liang K, Hsu JM, Albarracin C, Mills GB, Hung MC, Fan ZOncogeneBrk/PTK6 sustains activated EGFR signaling through inhibiting EGFR degradation and transactivating EGFR. Oncogene. 2012 Oct 04; 31(40):4372-83.Oncogene2012-01-09T00:00:002012Brk/PTK6 sustains activated EGFR signaling through inhibiting EGFR degradation and transactivating EGFR.22895267Duan X, Sneige N, Gullett AE, Prieto VG, Resetkova E, Andino LM, Wu Y, Gilcrease MZ, Bedrosian I, Dawood S, Arun B, Albarracin CTThe American journal of surgical pathologyInvasive paget disease of the breast: clinicopathologic study of an underrecognized entity in the breast. Am J Surg Pathol. 2012 Sep; 36(9):1353-8.Am J Surg Pathol2012-09-01T00:00:002012Invasive paget disease of the breast: clinicopathologic study of an underrecognized entity in the breast.25551582Caruso JA, Karakas C, Zhang J, Yi M, Albarracin C, Sahin A, Bondy M, Liu J, Hunt KK, Keyomarsi KBreast cancer research : BCRElafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrence. Breast Cancer Res. 2014; 16(6):3417.Breast Cancer Res2014-01-01T00:00:002014Elafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrence.26000884Bhardwaj A, Ganesan N, Tachibana K, Rajapakshe K, Albarracin CT, Gunaratne PH, Coarfa C, Bedrosian IPloS oneAnnexin A1 Preferentially Predicts Poor Prognosis of Basal-Like Breast Cancer Patients by Activating mTOR-S6 Signaling. PLoS One. 2015; 10(5):e0127678.PLoS One2015-05-22T00:00:002015Annexin A1 Preferentially Predicts Poor Prognosis of Basal-Like Breast Cancer Patients by Activating mTOR-S6 Signaling.Authorship 26755912Authorship 2682982Authorship 26882310Authorship 270637917211865Wang KL, Wu TT, Choi IS, Wang H, Resetkova E, Reseetkova E, Correa AM, Hofstetter WL, Swisher SG, Ajani JA, Rashid A, Albarracin CTCancerExpression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome. Cancer. 2007 Feb 15; 109(4):658-67.Cancer2007-02-15T00:00:002007Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome.18776816Cao Y, Li Y, Edelweiss M, Arun B, Rosen D, Resetkova E, Wu Y, Liu J, Sahin A, Albarracin CTApplied immunohistochemistry & molecular morphology : AIMMLoss of annexin A1 expression in breast cancer progression. Appl Immunohistochem Mol Morphol. 2008 Dec; 16(6):530-4.Appl Immunohistochem Mol Morphol2008-12-01T00:00:002008Loss of annexin A1 expression in breast cancer progression.18779615Atchley DP, Albarracin CT, Lopez A, Valero V, Amos CI, Gonzalez-Angulo AM, Hortobagyi GN, Arun BKJournal of clinical oncology : official journal of the American Society of Clinical OncologyClinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol. 2008 Sep 10; 26(26):4282-8.J Clin Oncol2008-09-10T00:00:002008Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer.22486256Geyer FC, Lacroix-Triki M, Colombo PE, Patani N, Gauthier A, Natrajan R, Lambros MB, Khalifeh I, Albarracin C, Orru S, Marchi? C, Sapino A, Mackay A, Weigelt B, Schmitt FC, Wesseling J, Sneige N, Reis-Filho JSHistopathologyMolecular evidence in support of the neoplastic and precursor nature of microglandular adenosis. Histopathology. 2012 May; 60(6B):E115-30.Histopathology2012-04-04T00:00:002012Molecular evidence in support of the neoplastic and precursor nature of microglandular adenosis.Authorship 2749306Authorship 275544819047281Dawood S, Broglio K, Kau SW, Green MC, Giordano SH, Meric-Bernstam F, Buchholz TA, Albarracin C, Yang WT, Hennessy BT, Hortobagyi GN, Gonzalez-Angulo AMJournal of clinical oncology : official journal of the American Society of Clinical OncologyTriple receptor-negative breast cancer: the effect of race on response to primary systemic treatment and survival outcomes. J Clin Oncol. 2009 Jan 10; 27(2):220-6.J Clin Oncol2008-12-01T00:00:002008Triple receptor-negative breast cancer: the effect of race on response to primary systemic treatment and survival outcomes.22899286Li X, Deavers MT, Guo M, Liu P, Gong Y, Albarracin CT, Middleton LP, Huo LModern pathology : an official journal of the United States and Canadian Academy of Pathology, IncThe effect of prolonged cold ischemia time on estrogen receptor immunohistochemistry in breast cancer. Mod Pathol. 2013 Jan; 26(1):71-8.Mod Pathol2012-08-17T00:00:002012The effect of prolonged cold ischemia time on estrogen receptor immunohistochemistry in breast cancer.Authorship 2788385Authorship 2789835Authorship 2874796Authorship 2893578Authorship 2899059Authorship 29462810Authorship 2968417Authorship 2988558Authorship 3017072Authorship 3028944Authorship 3035107Authorship 304440523947655Krishnamurthy S, Mathews K, McClure S, Murray M, Gilcrease M, Albarracin C, Spinosa J, Chang B, Ho J, Holt J, Cohen A, Giri D, Garg K, Bassett RL, Liang KArchives of pathology & laboratory medicineMulti-institutional comparison of whole slide digital imaging and optical microscopy for interpretation of hematoxylin-eosin-stained breast tissue sections. Arch Pathol Lab Med. 2013 Dec; 137(12):1733-9.Arch Pathol Lab Med2013-08-15T00:00:002013Multi-institutional comparison of whole slide digital imaging and optical microscopy for interpretation of hematoxylin-eosin-stained breast tissue sections.24796968Elsayegh N, Kuerer HM, Lin H, Gutierrez Barrera AM, Jackson M, Muse KI, Litton JK, Albarracin C, Afrough A, Hortobagyi GN, Arun BKAnnals of surgical oncologyPredictors that influence contralateral prophylactic mastectomy election among women with ductal carcinoma in situ who were evaluated for BRCA genetic testing. Ann Surg Oncol. 2014 Oct; 21(11):3466-72.Ann Surg Oncol2014-05-06T00:00:002014Predictors that influence contralateral prophylactic mastectomy election among women with ductal carcinoma in situ who were evaluated for BRCA genetic testing.24811059Bhardwaj A, Rosen D, Liu M, Liu Y, Hao Q, Ganesan N, Etzel CJ, Gullett A, Albarracin CT, Bedrosian IPloS oneSuppression of Akt-mTOR pathway-a novel component of oncogene induced DNA damage response barrier in breast tumorigenesis. PLoS One. 2014; 9(5):e97076.PLoS One2014-05-08T00:00:002014Suppression of Akt-mTOR pathway-a novel component of oncogene induced DNA damage response barrier in breast tumorigenesis.25739674Song S, Honjo S, Jin J, Chang SS, Scott AW, Chen Q, Kalhor N, Correa AM, Hofstetter WL, Albarracin CT, Wu TT, Johnson RL, Hung MC, Ajani JAClinical cancer research : an official journal of the American Association for Cancer ResearchThe Hippo Coactivator YAP1 Mediates EGFR Overexpression and Confers Chemoresistance in Esophageal Cancer. Clin Cancer Res. 2015 Jun 01; 21(11):2580-90.Clin Cancer Res2015-03-04T00:00:002015The Hippo Coactivator YAP1 Mediates EGFR Overexpression and Confers Chemoresistance in Esophageal Cancer.25878190Moulder S, Helgason T, Janku F, Wheler J, Moroney J, Booser D, Albarracin C, Morrow PK, Atkins J, Koenig K, Gilcrease M, Kurzrock RAnnals of oncology : official journal of the European Society for Medical OncologyInhibition of the phosphoinositide 3-kinase pathway for the treatment of patients with metastatic metaplastic breast cancer. Ann Oncol. 2015 Jul; 26(7):1346-52.Ann Oncol2015-04-15T00:00:002015Inhibition of the phosphoinositide 3-kinase pathway for the treatment of patients with metastatic metaplastic breast cancer.25932963Peintinger F, Sinn B, Hatzis C, Albarracin C, Downs-Kelly E, Morkowski J, Gould R, Symmans WFModern pathology : an official journal of the United States and Canadian Academy of Pathology, IncReproducibility of residual cancer burden for prognostic assessment of breast cancer after neoadjuvant chemotherapy. Mod Pathol. 2015 Jul; 28(7):913-20.Mod Pathol2015-05-01T00:00:002015Reproducibility of residual cancer burden for prognostic assessment of breast cancer after neoadjuvant chemotherapy.25975189Sevcikova K, Zhuang Z, Garcia-Manero G, Alvarez RH, Kantarjian HM, Mego M, Albarracin C, Tang G, Strom SS, Medeiros LJ, Hortobagyi GN, Reuben JM, Khoury JDLeukemiaComprehensive analysis of factors impacting risks and outcomes of therapy-related myeloid neoplasms following breast cancer treatment. Leukemia. 2016 Jan; 30(1):242-7.Leukemia2015-05-15T00:00:002015Comprehensive analysis of factors impacting risks and outcomes of therapy-related myeloid neoplasms following breast cancer treatment.26108797Caruso JA, Karakas C, Zhang J, Yi M, Albarracin C, Sahin A, Bondy M, Liu J, Hunt KK, Keyomarsi KBreast cancer research : BCRErratum to: Elafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrence. Breast Cancer Res. 2015 Jun 25; 17:87.Breast Cancer Res2015-06-25T00:00:002015Erratum to: Elafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrence.26280679Sanford RA, Song J, Gutierrez-Barrera AM, Profato J, Woodson A, Litton JK, Bedrosian I, Albarracin CT, Valero V, Arun BCancerHigh incidence of germline BRCA mutation in patients with ER low-positive/PR low-positive/HER-2 neu negative tumors. Cancer. 2015 Oct 01; 121(19):3422-7.Cancer2015-08-17T00:00:002015High incidence of germline BRCA mutation in patients with ER low-positive/PR low-positive/HER-2 neu negative tumors.26664775Miller T, Albarracin C, Carkaci S, Whitman GJ, Adrada BEJournal of clinical imaging scienceRare Malignant Tumors of the Breast. J Clin Imaging Sci. 2015; 5:58.J Clin Imaging Sci2015-10-30T00:00:002015Rare Malignant Tumors of the Breast.74Professor14Associate ProfessorBreast Surgical Oncology22445362Raghunathan A, Olar A, Vogel H, Parker JR, Coventry SC, Debski R, Albarracin CT, Aldape KD, Cahill DP, Powell SZ, Fuller GNAnnals of diagnostic pathologyIsocitrate dehydrogenase 1 R132H mutation is not detected in angiocentric glioma. Ann Diagn Pathol. 2012 Aug; 16(4):255-9.Ann Diagn Pathol2012-03-23T00:00:002012Isocitrate dehydrogenase 1 R132H mutation is not detected in angiocentric glioma.22014043Perry KD, Reynolds C, Rosen DG, Edgerton ME, T Albarracin C, Gilcrease MZ, Sahin AA, Abraham SC, Wu YHistopathologyMetastatic neuroendocrine tumour in the breast: a potential mimic of in-situ and invasive mammary carcinoma. Histopathology. 2011 Oct; 59(4):619-30.Histopathology2011-10-01T00:00:002011Metastatic neuroendocrine tumour in the breast: a potential mimic of in-situ and invasive mammary carcinoma.Authorship 841528Authorship 847974Authorship 848931Authorship 852770Authorship 856441Authorship 859232Authorship 859604Authorship 861229Authorship 861975Authorship 863028Authorship 863221Authorship 863929Authorship 865692Authorship 865908Journal of Clinical Imaging ScienceRare Malignant Tumors of the Breast. Journal of Clinical Imaging Science. 5.Rare Malignant Tumors of the BreastCurrent Problems in Diagnostic RadiologyPseudoangiomatous Stromal Hyperplasia of the Breast. Current Problems in Diagnostic Radiology. Pseudoangiomatous Stromal Hyperplasia of the BreastBreast Cancer ResearchErratum to. Breast Cancer Research. 17.Erratum toClinical Cancer ResearchThe hippo coactivator YAP1 mediates EGFR overexpression and confers chemoresistance in esophageal cancer. Clinical Cancer Research. 21:2580-2590.The hippo coactivator YAP1 mediates EGFR overexpression and confers chemoresistance in esophageal cancerBreast Cancer ResearchElafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrence. Breast Cancer Research. 16.Elafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrencePLoS OneAnnexin A1 preferentially predicts poor prognosis of basal-like breast cancer patients by activating mTOR-S6 signaling. PLoS One. 10.Annexin A1 preferentially predicts poor prognosis of basal-like breast cancer patients by activating mTOR-S6 signalingArchives of Pathology and Laboratory MedicineMulti-institutional comparison of Whole slide digital imaging and optical microscopy for interpretation of hematoxylin-eosin-stained breast tissue sections. Archives of Pathology and Laboratory Medicine. 137:1733-1739.Multi-institutional comparison of Whole slide digital imaging and optical microscopy for interpretation of hematoxylin-eosin-stained breast tissue sectionsCurrent Breast Cancer ReportsKi67 as a Biomarker of Prognosis and Prediction. Current Breast Cancer Reports. 6:260-266.Ki67 as a Biomarker of Prognosis and PredictionCancerErratum. Cancer. 120:927.ErratumImmunological and molecular studies in breast tumors. 209-243.Immunological and molecular studies in breast tumorsBreast Cancer Research and TreatmentErratum. Breast Cancer Research and Treatment. 89:95.ErratumModern PathologyReproducibility of residual cancer burden for prognostic assessment of breast cancer after neoadjuvant chemotherapy. Modern Pathology. Reproducibility of residual cancer burden for prognostic assessment of breast cancer after neoadjuvant chemotherapyAnnals of Surgical OncologyLong-Term Safety of Observation in Selected Women Following Core Biopsy Diagnosis of Atypical Ductal Hyperplasia. Annals of Surgical Oncology. 1-7.Long-Term Safety of Observation in Selected Women Following Core Biopsy Diagnosis of Atypical Ductal HyperplasiaBreast DiseasesHedgehog overexpression is associated with stromal interactions and predicts for poor outcome in breast cancer. Breast Diseases. 22:383-384.Hedgehog overexpression is associated with stromal interactions and predicts for poor outcome in breast cancer22197544Olar A, Raghunathan A, Albarracin CT, Aldape KD, Cahill DP, Powell SZ, Goodman JC, Fuller GNAnnals of diagnostic pathologyAbsence of IDH1-R132H mutation predicts rapid progression of nonenhancing diffuse glioma in older adults. Ann Diagn Pathol. 2012 Jun; 16(3):161-70.Ann Diagn Pathol2011-12-24T00:00:002011Absence of IDH1-R132H mutation predicts rapid progression of nonenhancing diffuse glioma in older adults.D017305Chemicals & Drugs33390.968358Annexin A1D001943Disorders1430156220.176287Breast NeoplasmsD002285Disorders1926720.683453Carcinoma, Intraductal, NoninfiltratingAuthorship 9090555Authorship 9126677Authorship 91354912Authorship 9138412Authorship 9193558Authorship 92118810Authorship 9224864Authorship 92623415Authorship 938640426949063Raj SD, Sahani VG, Adrada BE, Scoggins ME, Albarracin CT, Woodtichartpreecha P, Posleman Monetto FE, Whitman GJCurrent problems in diagnostic radiologyPseudoangiomatous Stromal Hyperplasia of the Breast: Multimodality Review With Pathologic Correlation. Curr Probl Diagn Radiol. 2017 Mar - Apr; 46(2):130-135.Curr Probl Diagn Radiol2016-02-02T00:00:002016Pseudoangiomatous Stromal Hyperplasia of the Breast: Multimodality Review With Pathologic Correlation.27573525Menen RS, Ganesan N, Bevers T, Ying J, Coyne R, Lane D, Albarracin C, Bedrosian IAnnals of surgical oncologyLong-Term Safety of Observation in Selected Women Following Core Biopsy Diagnosis of Atypical Ductal Hyperplasia. Ann Surg Oncol. 2017 Jan; 24(1):70-76.Ann Surg Oncol2016-08-29T00:00:002016Long-Term Safety of Observation in Selected Women Following Core Biopsy Diagnosis of Atypical Ductal Hyperplasia.27893038Basho RK, Gilcrease M, Murthy RK, Helgason T, Karp DD, Meric-Bernstam F, Hess KR, Herbrich SM, Valero V, Albarracin C, Litton JK, Chavez-MacGregor M, Ibrahim NK, Murray JL, Koenig KB, Hong D, Subbiah V, Kurzrock R, Janku F, Moulder SLJAMA oncologyTargeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab. JAMA Oncol. 2017 Apr 01; 3(4):509-515.JAMA Oncol2017-04-01T00:00:002017Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab.28125801Chen H, Singh RR, Lu X, Huo L, Yao H, Aldape K, Abraham R, Virani S, Mehrotra M, Mishra BM, Bousamra A, Albarracin C, Wu Y, Roy-Chowdhuri S, Kanagal-Shamanna R, Routbort MJ, Medeiros LJ, Patel KP, Broaddus R, Sahin A, Luthra ROncotargetGenome-wide copy number aberrations and HER2 and FGFR1 alterations in primary breast cancer by molecular inversion probe microarray. Oncotarget. 2017 02 14; 8(7):10845-10857.Oncotarget2017-02-14T00:00:002017Genome-wide copy number aberrations and HER2 and FGFR1 alterations in primary breast cancer by molecular inversion probe microarray.28608612Akay CL, Albarracin C, Torstenson T, Bassett R, Mittendorf EA, Yi M, Kuerer HM, Babiera GV, Bedrosian I, Hunt KK, Hwang RFThe breast journalFactors impacting the accuracy of intra-operative evaluation of sentinel lymph nodes in breast cancer. Breast J. 2018 01; 24(1):28-34.Breast J2017-06-13T00:00:002017Factors impacting the accuracy of intra-operative evaluation of sentinel lymph nodes in breast cancer.28742682Tadros AB, Smith BD, Shen Y, Lin H, Krishnamurthy S, Lucci A, Barcenas CH, Hwang RF, Rauch G, Santiago L, Strom EA, DeSnyder SM, Yang WT, Black DM, Albarracin CT, Chavez-MacGregor M, Hunt KK, Kuerer HMAnnals of surgeryDuctal Carcinoma In Situ and Margins <2?mm: Contemporary Outcomes With Breast Conservation. Ann Surg. 2019 01; 269(1):150-157.Ann Surg2019-01-01T00:00:002019Ductal Carcinoma In Situ and Margins <2?mm: Contemporary Outcomes With Breast Conservation.28928852Kuerer HM, Smith BD, Chavez-MacGregor M, Albarracin C, Barcenas CH, Santiago L, Edgerton ME, Rauch GM, Giordano SH, Sahin A, Krishnamurthy S, Woodward W, Tripathy D, Yang WT, Hunt KKJournal of CancerDCIS Margins and Breast Conservation: MD Anderson Cancer Center Multidisciplinary Practice Guidelines and Outcomes. J Cancer. 2017; 8(14):2653-2662.J Cancer2017-08-22T00:00:002017DCIS Margins and Breast Conservation: MD Anderson Cancer Center Multidisciplinary Practice Guidelines and Outcomes.29470805Clifton K, Gutierrez-Barrera A, Ma J, Bassett R, Litton J, Kuerer H, Moulder S, Albarracin C, Hortobagyi G, Arun BBreast cancer research and treatmentAdjuvant versus neoadjuvant chemotherapy in triple-negative breast cancer patients with BRCA mutations. Breast Cancer Res Treat. 2018 Jul; 170(1):101-109.Breast Cancer Res Treat2018-02-22T00:00:002018Adjuvant versus neoadjuvant chemotherapy in triple-negative breast cancer patients with BRCA mutations.30537987Bhardwaj A, Singh H, Trinidad CM, Albarracin CT, Hunt KK, Bedrosian IBreast cancer research : BCRThe isomiR-140-3p-regulated mevalonic acid pathway as a potential target for prevention of triple negative breast cancer. Breast Cancer Res. 2018 12 11; 20(1):150.Breast Cancer Res2018-12-11T00:00:002018The isomiR-140-3p-regulated mevalonic acid pathway as a potential target for prevention of triple negative breast cancer.D018270Disorders28712140.592937Carcinoma, Ductal, BreastPathologyAuthorship 9438111030139837Basho RK, Yam C, Gilcrease M, Murthy RK, Helgason T, Karp DD, Meric-Bernstam F, Hess KR, Valero V, Albarracin C, Litton JK, Chavez-MacGregor M, Hong D, Kurzrock R, Hortobagyi GN, Janku F, Moulder SLThe oncologistComparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast Cancer. Oncologist. 2018 11; 23(11):1300-1309.Oncologist2018-08-23T00:00:002018Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast Cancer.D00006958410140.974743Unilateral Breast Neoplasms21075308Liang K, Esteva FJ, Albarracin C, Stemke-Hale K, Lu Y, Bianchini G, Yang CY, Li Y, Li X, Chen CT, Mills GB, Hortobagyi GN, Mendelsohn J, Hung MC, Fan ZCancer cellRecombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation. Cancer Cell. 2010 Nov 16; 18(5):423-35.Cancer Cell2010-11-16T00:00:002010Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation.21334720Tian Z, Wei B, Tang F, Wei W, Gilcrease MZ, Huo L, Albarracin CT, Resetkova E, Middleton L, Sahin A, Xing Y, Hunt KK, Chen J, Bu H, Rashid A, Abraham SC, Wu YHuman pathologyPrognostic significance of tumor grading and staging in mammary carcinomas with neuroendocrine differentiation. Hum Pathol. 2011 Aug; 42(8):1169-77.Hum Pathol2011-02-21T00:00:002011Prognostic significance of tumor grading and staging in mammary carcinomas with neuroendocrine differentiation.Authorship 947248431087426Eghtedari M, Le-Petross H, Babiera GV, Albarracin CT, Hess KR, Woodtichartpreecha P, Whitman GJThe breast journalNot all patients with a diagnosis of a radial scar require excision. Breast J. 2019 07; 25(4):792-794.Breast J2019-05-13T00:00:002019Not all patients with a diagnosis of a radial scar require excision.Authorship 954197531432749Asik E, Akpinar Y, Caner A, Kahraman N, Guray T, Volkan M, Albarracin C, Pataer A, Arun B, Ozpolat BNanomedicine (London, England)EF2-kinase targeted cobalt-ferrite siRNA-nanotherapy suppresses BRCA1-mutated breast cancer. Nanomedicine (Lond). 2019 09; 14(17):2315-2338.Nanomedicine (Lond)2019-08-21T00:00:002019EF2-kinase targeted cobalt-ferrite siRNA-nanotherapy suppresses BRCA1-mutated breast cancer.Authorship 977596632033821Karbasian N, Sohrabi S, Omofoye TS, Le-Petross H, Arun BK, Albarracin CT, Hess KR, Gutierrez-Barrera AM, Whitman GJCurrent problems in diagnostic radiologyImaging Features of Triple Negative Breast Cancer and the Effect of BRCA Mutations. Curr Probl Diagn Radiol. 2021 May-Jun; 50(3):303-307.Curr Probl Diagn Radiol2020-01-08T00:00:002020Imaging Features of Triple Negative Breast Cancer and the Effect of BRCA Mutations.Authorship 10020421833011748Ai D, Yao J, Yang F, Huo L, Chen H, Lu W, Soto LMS, Jiang M, Raso MG, Wang S, Bell D, Liu J, Wang H, Tan D, Torres-Cabala C, Gan Q, Wu Y, Albarracin C, Hung MC, Meric-Bernstam F, Wistuba II, Prieto VG, Sahin AA, Ding QModern pathology : an official journal of the United States and Canadian Academy of Pathology, IncTRPS1: a highly sensitive and specific marker for breast carcinoma, especially for triple-negative breast cancer. Mod Pathol. 2021 04; 34(4):710-719.Mod Pathol2020-10-03T00:00:002020TRPS1: a highly sensitive and specific marker for breast carcinoma, especially for triple-negative breast cancer.Authorship 10065641133289978Roy M, Teshome M, Damodaran S, Sahin AA, Khazai L, Arribas E, Candelaria RP, Scoggins ME, Lane DL, Giordano SH, Albarracin CT, Prieto VG, Nagarajan PThe American Journal of dermatopathologyMale Mammary Paget Disease: A Tale of 2 Contrasting Cases. Am J Dermatopathol. 2020 Dec; 42(12):981-985.Am J Dermatopathol2020-12-01T00:00:002020Male Mammary Paget Disease: A Tale of 2 Contrasting Cases.Authorship 1010430533528758Yang L, Roy M, Lin H, Shen Y, Albarracin C, Huo L, Chen H, Wei B, Bedrosian I, Bu H, Wu YBreast cancer research and treatmentValidation of prognostic significance of the proposed uniform classification framework in neuroendocrine neoplasms of the breast. Breast Cancer Res Treat. 2021 Apr; 186(2):403-415.Breast Cancer Res Treat2021-02-02T00:00:002021Validation of prognostic significance of the proposed uniform classification framework in neuroendocrine neoplasms of the breast.Authorship 1015896233813685McLemore LE, Albarracin CT, Gruschkus SK, Bassett RL, Wu Y, Dhamne S, Yim I, Lin K, Bedrosian I, Sneige N, Chen HBreast cancer research and treatmentHER2 testing in breast cancers: comparison of assays and interpretation using ASCO/CAP 2013 and 2018 guidelines. Breast Cancer Res Treat. 2021 May; 187(1):95-104.Breast Cancer Res Treat2021-04-03T00:00:002021HER2 testing in breast cancers: comparison of assays and interpretation using ASCO/CAP 2013 and 2018 guidelines.Authorship 1016943433893908Bhardwaj A, Embury MD, Rojo RD, Albarracin C, Bedrosian IBreast cancer research and treatmentEfficacy of fluvastatin and aspirin for prevention of hormonally insensitive breast cancer. Breast Cancer Res Treat. 2021 Jun; 187(2):363-374.Breast Cancer Res Treat2021-04-24T00:00:002021Efficacy of fluvastatin and aspirin for prevention of hormonally insensitive breast cancer.Authorship 10172507Authorship 1017287533914469Kilgore LJ, Yi M, Bevers T, Coyne R, Marita L, Lane D, Albarracin C, Bedrosian IAnnals of surgeryRisk of Breast Cancer in Selected Women With Atypical Ductal Hyperplasia Who do not Undergo Surgical Excision. Ann Surg. 2022 Dec 01; 276(6):e932-e936.Ann Surg2021-03-04T00:00:002021Risk of Breast Cancer in Selected Women With Atypical Ductal Hyperplasia Who do not Undergo Surgical Excision.33916118Chen X, Yang D, Carey JPW, Karakas C, Albarracin C, Sahin AA, Arun BK, Guray Durak M, Li M, Kohansal M, Bui TN, Ha MJ, Hunt KK, Keyomarsi KCancersTargeting Replicative Stress and DNA Repair by Combining PARP and Wee1 Kinase Inhibitors Is Synergistic in Triple Negative Breast Cancers with Cyclin E or BRCA1 Alteration. Cancers (Basel). 2021 Apr 01; 13(7).Cancers (Basel)2021-04-01T00:00:002021Targeting Replicative Stress and DNA Repair by Combining PARP and Wee1 Kinase Inhibitors Is Synergistic in Triple Negative Breast Cancers with Cyclin E or BRCA1 Alteration.Authorship 10403321235063444Wang J, Wang WL, Sun H, Huo L, Wu Y, Chen H, Gan Q, Meis JM, Maloney N, Lazar AJ, Yoon EC, Albarracin CT, Krishnamurthy S, Middleton LP, Resetkova E, Yu W, Tan D, Lu W, Solis Soto LM, Wang S, Wistuba II, Parwani AV, Prieto VG, Sahin AA, Li Z, Ding QHuman pathologyExpression of TRPS1 in phyllodes tumor and sarcoma of the breast. Hum Pathol. 2022 03; 121:73-80.Hum Pathol2022-01-19T00:00:002022Expression of TRPS1 in phyllodes tumor and sarcoma of the breast.Authorship 104378910Authorship 1044262435447141Zhou P, Chang N, Abraham SC, Albarracin CT, Huo L, Chen H, Ding Q, Resetkova E, Middleton LP, Sahin AA, Bu H, Wu YHuman pathologyMetastatic nonhematopoietic neoplasms to the breast: a study of 238 cases. Hum Pathol. 2022 07; 125:59-67.Hum Pathol2022-04-18T00:00:002022Metastatic nonhematopoietic neoplasms to the breast: a study of 238 cases.35413381Yoon EC, Wang G, Parkinson B, Huo L, Peng Y, Wang J, Salisbury T, Wu Y, Chen H, Albarracin CT, Resetkova E, Middleton LP, Krishnamurthy S, Gan Q, Sun H, Huang X, Shen T, Chen W, Parwani AV, Sahin AA, Li Z, Ding QHuman pathologyTRPS1, GATA3, and SOX10 expression in triple-negative breast carcinoma. Hum Pathol. 2022 07; 125:97-107.Hum Pathol2022-04-09T00:00:002022TRPS1, GATA3, and SOX10 expression in triple-negative breast carcinoma.Authorship 1064487836808637Cho WC, Ding Q, Wang WL, Nagarajan P, Curry JL, Torres-Cabala CA, Ivan D, Albarracin CT, Sahin A, Prieto VG, Aung PPJournal of cutaneous pathologyImmunohistochemical expression of TRPS1 in mammary Paget disease, extramammary Paget disease, and their close histopathologic mimics. J Cutan Pathol. 2023 May; 50(5):434-440.J Cutan Pathol2023-03-01T00:00:002023Immunohistochemical expression of TRPS1 in mammary Paget disease, extramammary Paget disease, and their close histopathologic mimics.Authorship 10653811236878823Wang M, Ding Q, Gu J, Sfamenos SM, Huo L, Tang Z, Sun H, Robinson M, Tang G, Lim B, Wu Y, Albarracin CT, Sahin AA, Chen HClinical breast cancerBreast Cancer With a HER2 FISH Group 2 Result: Should HER2 Tests be Repeated? Clin Breast Cancer. 2023 06; 23(4):415-422.Clin Breast Cancer2023-02-12T00:00:002023Breast Cancer With a HER2 FISH Group 2 Result: Should HER2 Tests be Repeated?Authorship 10788615Authorship 1077316837566192Yang L, Lin H, Shen Y, Roy M, Albarracin C, Ding Q, Huo L, Chen H, Wei B, Bu H, Bedrosian I, Wu YBreast cancer research and treatmentClinical outcome and therapeutic impact on neuroendocrine neoplasms of the breast: a national cancer database study. Breast Cancer Res Treat. 2023 Nov; 202(1):23-32.Breast Cancer Res Treat2023-08-11T00:00:002023Clinical outcome and therapeutic impact on neuroendocrine neoplasms of the breast: a national cancer database study.37586834Ye Q, Chen H, Han C, Peng Y, Huang X, Sun H, Wu Y, Albarracin CT, Middleton LP, Sahin AA, Huo L, Ding QJournal of clinical pathologyNuclear staining for pan-Trk by immunohistochemistry is highly specific for secretory carcinoma of breast: pan-Trk in various subtypes of breast carcinoma. J Clin Pathol. 2023 Aug 16.J Clin Pathol2023-08-16T00:00:002023Nuclear staining for pan-Trk by immunohistochemistry is highly specific for secretory carcinoma of breast: pan-Trk in various subtypes of breast carcinoma.Authorship 10800058Authorship 10800361237744342Mistretta B, Rankothgedera S, Castillo M, Rao M, Holloway K, Bhardwaj A, El Noafal M, Albarracin C, El-Zein R, Rezaei H, Su X, Akbani R, Shao XM, Czerniecki BJ, Karchin R, Bedrosian I, Gunaratne PHFrontiers in immunologyChimeric RNAs reveal putative neoantigen peptides for developing tumor vaccines for breast cancer. Front Immunol. 2023; 14:1188831.Front Immunol2023-09-06T00:00:002023Chimeric RNAs reveal putative neoantigen peptides for developing tumor vaccines for breast cancer.37751078Wang J, Chen H, Koenig J, Wu Y, Bedrosian I, Arun B, Ding Q, Khazai L, Resetkova E, Huo L, Sneige N, Albarracin CBreast cancer research and treatmentDiscordance of Oncotype DX scores in synchronous bilateral and unilateral multifocal breast cancers. Breast Cancer Res Treat. 2024 Jan; 203(1):73-83.Breast Cancer Res Treat2023-09-26T00:00:002023Discordance of Oncotype DX scores in synchronous bilateral and unilateral multifocal breast cancers.Authorship 10865261638201434Zheng L, Luthra R, Alvarez HA, San Lucas FA, Duose DY, Wistuba II, Fuller GN, Ballester LY, Roy-Chowdhuri S, Sweeney KJ, Rashid A, Yang RK, Chen W, Liu A, Wu Y, Albarracin C, Patel KP, Routbort MJ, Sahin AA, Ding Q, Chen HCancersIntragenic EGFR::EGFR.E1E8 Fusion (EGFRvIII) in 4331 Solid Tumors. Cancers (Basel). 2023 Dec 19; 16(1).Cancers (Basel)2023-12-19T00:00:002023Intragenic EGFR::EGFR.E1E8 Fusion (EGFRvIII) in 4331 Solid Tumors.Authorship 1087820338262580Salem A, Wu Y, Albarracin CT, Middleton LP, Kalhor N, Peng Y, Huang X, Aung PP, Chen H, Sahin AA, Ding QHuman pathologyA Comparative Evaluation of TRPS1 and GATA3 in adenoid cystic, secretory, and acinic cell carcinomas of the breast and salivary gland. Hum Pathol. 2024 Mar; 145:42-47.Hum Pathol2024-01-21T00:00:002024A Comparative Evaluation of TRPS1 and GATA3 in adenoid cystic, secretory, and acinic cell carcinomas of the breast and salivary gland.Authorship 1090251938441847Sun H, Kang EY, Chen H, Sweeney KJ, Suchko M, Wu Y, Wen J, Krishnamurthy S, Albarracin CT, Ding QQ, Foo WC, Sahin AABreast cancer research and treatmentImmunohistochemical assessment of HER2 low breast cancer: interobserver reproducibility and correlation with digital image analysis. Breast Cancer Res Treat. 2024 Mar 05.Breast Cancer Res Treat2024-03-05T00:00:002024Immunohistochemical assessment of HER2 low breast cancer: interobserver reproducibility and correlation with digital image analysis.true1ProfessorProfessortrue1Associate ProfessorAssociate Professortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1Associate ProfessorAssociate Professortrue1Associate ProfessorAssociate Professortrue1ProfessorProfessor19342367Maru DM, Singh RR, Hannah C, Albarracin CT, Li YX, Abraham R, Romans AM, Yao H, Luthra MG, Anandasabapathy S, Swisher SG, Hofstetter WL, Rashid A, Luthra RThe American journal of pathologyMicroRNA-196a is a potential marker of progression during Barrett's metaplasia-dysplasia-invasive adenocarcinoma sequence in esophagus. Am J Pathol. 2009 May; 174(5):1940-8.Am J Pathol2009-03-26T00:00:002009MicroRNA-196a is a potential marker of progression during Barrett's metaplasia-dysplasia-invasive adenocarcinoma sequence in esophagus.